HAMBURG, Germany and LAGOS, Nigeria, Dec. 4, 2024 /PRNewswire/ — Over 64 million Nigerians now conduct their banking transactions through accounts safeguarded by advanced biometric technology. This cutting-edge solution was developed by DERMALOG, Germany’s leading manufacturer of biometric identification systems.
In 2015, DERMALOG implemented a biometric system for 23 Nigerian banks and the country’s central bank, enabling customers to register their accounts using fingerprint and facial recognition. By verifying identity through biometric features, subsequent transactions, such as deposits and withdrawals, can be completed quickly and securely.
The identity verification system developed by DERMALOG is deployed nationwide in Nigeria. It plays a crucial role in combating fraud in the financial services sector and protecting account holders from unauthorized access to their savings. Additionally, the solution simplifies access to financial services for Nigerian citizens, marking a substantial stride towards greater financial inclusion.
“Over the past decade, our innovative technology has made a vital contribution to enhancing security in Africa’s largest economy. Our collaboration with the Nigerian banking sector is a prime example of how biometrics can streamline access to essential everyday services while significantly improving security,” said Günther Mull, CEO of DERMALOG.
DERMALOG is Germany’s pioneer in biometrics and the country’s largest manufacturer of biometric systems. Founded in 1995, the company develops fingerprint, facial, and iris recognition identification solutions. DERMALOG’s technology is now used worldwide in more than 100 countries by 260 governmental authorities and companies for applications such as border control, ID issuance and banking services.
Picture is available at AP.
Caption: In 2015, DERMALOG implemented a biometric system for 23 Nigerian banks and the country’s central bank, enabling customers to register their accounts using fingerprint and facial recognition.
Press contact:
Sven Böckler
Media Relations
DERMALOG Identification Systems GmbH
+49 (0) 40 13 227 0
[email protected]
www.dermalog.com
ข่าวที่เกี่ยวข้อง
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
